Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism

Journal of Pharmaceutical Sciences

Volumn 99, Issue 11, 2010, Pages 4554-4564

  Bai, Shuhua ^a,b   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b HUSSON UNIVERSITY   (United States)

Author keywords

Deep vein thrombosis; Liposomes; Low molecular weight heparin; Pegylation; Pulmonary embolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; MACROGOL 2000; MACROGOL 5000; PHOSPHOETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; HYDRATION; LUNG EMBOLISM; NONHUMAN; PARTICLE SIZE; RAT;

EID: 78149351522     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22160     Document Type: Article

References (41)

1. Segal JB, Eng J, Tamariz LJ, Bass EB. 2007. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med 5: 63-73.
2. Haines S, Zeolla M, Witt D. 2005. Venous thromboembolism. Pharmacotherapy: A pathophysiological approach. 6th edition. New York: McGraw-Hill Company.
3. Hull RD, Pineo GF, Stein P. 1998. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring. Int Angiol 17: 213-224.
4. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, Kovacs J. 1998. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch Intern Med 158: 1809-1812.
5. Bai S, Thomas C, Ahsan F. 2007. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci 96: 2090-2106.
6. Yang T, Mustafa F, Bai S, Ahsan F. 2004. Pulmonary delivery of low molecular weight heparins. Pharm Res 21: 2009-2016.
7. Betz G, Imboden R, Imanidis G. 2001. Interaction of liposome formulations with human skin in vitro. Int J Pharm 229: 117-129.
8. Song YK, Kim CK. 2006. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials 27: 271-280.
9. Gorski G, Szopinski P, Michalak J, Marianowska A, Borkowski M, Geremek M, Trochimczuk M, Brotanek J, Sarnik S, Semenka J, Wilkowski D, Noszczyk W. 2005. Liposomal heparin spray: A new formula in adjunctive treatment of superficial venous thrombosis. Angiology 56: 9-17.
10. Bai S, Gupta V, Ahsan F. 2009. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study. Eur J Pharm Sci 38: 165-171.
11. Szoka F Jr, Papahadjopoulos D. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75: 4194-4198.
12. Brgles M, Habjanec L, Halassy B, Tomasic J. 2009. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. Vaccine 27: 5435-5442.
13. Heeremans JL, Gerritsen HR, Meusen SP, Mijnheer FW, Gangaram Panday RS, Prevost R, Kluft C, Crommelin DJ. 1995. The preparation of tissue-type plasminogen activator (t-PA) containing liposomes: Entrapment efficiency and ultracentrifugation damage. J Drug Target 3: 301-310.
14. Clozel JP, Holvoet P, Tschopp T. 1988. Experimental pulmonary embolus in the rat: A new in vivo model to test thrombolytic drugs. J Cardiovasc Pharmacol 12: 520-525.
15. Stassen JM, Lijnen HR, Kieckens L, Collen D. 1991. Small animal thrombosis models for the evaluation of thrombolytic agents. Circulation 83: IV65-IV72.
16. Gonze MD, Salartash K, Sternbergh WC III, Baughman RA, Leone-Bay A, Money SR. 2000. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 101: 2658-2661.
17. Salartash K, Gonze MD, Leone-Bay A, Baughman R, Sternbergh WC III, Money SR. 1999. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. J Vasc Surg 30: 526-531.
18. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. 2008. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 97: 4696-4740.
19. Gabizon A, Papahadjopoulos D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 6949-6953.
20. Woodle MC, Lasic DD. 1992. Sterically stabilized liposomes. Biochim Biophys Acta 1113: 171-199.
21. Bedu-Addo F, Huang L. 1995. Interaction of PEG-phopholipid conjugates with pholspholipid: Implications in liposomal drug delivery. Adv Drug Deliv Rev 15: 235-247.
22. Yoshioka H. 1991. Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma. Biomaterials 12: 861-864.
23. Hong MS, Lim SJ, Lee MK, Kim YB, Kim CK. 2001. Prolonged blood circulation of methotrexate by modulation of liposomal composition. Drug Deliv 8: 231-237.
24. Kulkarni SB, Betageri GV, Singh M. 1995. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 12: 229-246.
25. Nallamothu R, Wood GC, Kiani MF, Moore BM, Horton FP, Thoma LA. 2006. A targeted liposome delivery system for combretastatin A4: Formulation optimization through drug loading and in vitro release studies. PDA J Pharm Sci Technol 60: 144-155.
26. Rawat A, Majumder QH, Ahsan F. 2008. Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation. J Control Release 128: 224-232.
27. Angst MS, Drover DR. 2006. Pharmacology of drugs formulated with DepoFoam: A sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet 45: 1153-1176.
28. Bradley AJ, Devine DV. 1998. The complement system in liposome clearance: Can complement deposition be inhibited? Adv Drug Deliv Rev 32: 19-29.
29. Harashima H, Sakata K, Funato K, Kiwada H. 1994. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 11: 402-406.
30. Yan X, Scherphof GL, Kamps JA. 2005. Liposome opsonization. J Liposome Res 15: 109-139.
31. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. 2000. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292: 1071-1079.
32. Ishida T, Atobe K, Wang X, Kiwada H. 2006. Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection. J Control Release 115: 251-258.
33. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. 2001. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298: 607-612.
34. Johnston MJ, Edwards K, Karlsson G, Cullis PR. 2008. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res 18: 145-157.
35. Maruyama K, Yuda T, Okamoto A, Kojima S, Suginaka A, Iwatsuru M. 1992. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1128: 44-49.
36. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. 1998. Low-molecular-weight heparins: Pharmacologic profile and product differentiation. Am J Cardiol 82: 3L-10L.
37. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. 1998. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365-377.
38. Kleinschmidt K, Charles R. 2001. Pharmacology of low molecular weight heparins. Emerg Med Clin North Am 19: 1025-1049.
39. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. 1997. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78: 386-391.
40. Goldhaber SZ. 1998. Pulmonary embolism. N Engl J Med 339: 93-104.
41. Zed PJ, Tisdale JE, Borzak S. 1999. Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849-1857.